ANGANY
Entity

  • ANGANY

    Created in 2017
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    1,835 1,835

  • Activities

    deeptech biotech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    873 Rue Saint-Jean #200, Québec, QC G1R 1R2, Canada

    Québec

    Canada

  • Employees

    Scale: 11-50

    Estimated: 20

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    9 months, 1 week ago
Description
  • Value proposition

    Immunity Humanité

    ANGANY is an emerging, private pharmaceutical company, based in Quebec City, Canada. ANGANY has tackled the specific challenges of allergy to invent first-in class pharmaceuticals. ANGANY has developed an exclusive vaccine platform based on synthetic biology: the eBioparticle TM self-adjuvant vector. ANGANY also produces high quality, high purity allergens for diagnostic purposes. Finally, ANGANY has developed a flexible, fast and highly scalable 3rd generation plant production platform. ANGANY's vaccine approach opens the door to applications in cancer, infectious, autoimmune diseases and others. ANGANY is a Franco-Canadian collaboration led by Louis-Philippe Vézina, a renowned pharmaceutical entrepreneur.

    allergenes recombinants, immunotherapy, biotechnology, innovation, allergy, allergens, and therapeutics

  • Home | ANGANY

    ANGANY proposes a new generation of allergy therapeutics aimed at helping allergic people build their own protective response against the pecise cause of their allergy.

    • https://angany.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics